Gufic Biosciences share news, announcements and annual reports
NSE: GUFICBIOBSE: 509079Pharmaceuticals & BiotechnologySmall Cap
Gufic Biosciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1985 on BSE, Oct 2004 on NSE
Last close ₹413.55down ₹5.25 (1.25%)BSE ₹412.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹418.80.
30 Oct: open ₹416.90, high ₹423.00, low ₹407.70
52-week range of traded prices to 30 Oct 2026
₹268.00Low, 9 Mar 2026₹467.80High, 7 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,147 Cr959th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 56.46
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.24
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 70,25448.5% delivered
Gufic Biosciences share news and announcements
608 announcements, routine notices left out, newest first. Page 10 of 13.
Jul 2016
Jun 2016
8 Jun · Board meeting
May 2016
30 May · Board meeting
Apr 2016
Feb 2016
Dec 2015
Nov 2015
Oct 2015
1 Oct · Disclosure of Voting Pattern - Clause 35A
Sep 2015
Aug 2015
25 Aug · Code of Conduct under SEBI(PIT) Reg., 2015
14 Aug · Results
May 2015
30 May · Dividend
Board of Directors of the Company at its meeting held on May 29, 2015 has recommended a final dividend of Re 0.05 per equity shares. This proposal is subject to approval of shareholders at the ensuing Annual General Meeting.29 May · Results
Feb 2015
14 Feb · Results
Nov 2014
14 Nov · Management
Dr. M.G. Dhapalapur, Executive Director of the Company has resigned from the directorship of the Company due to pre-occupation his resignation was duley accepted by the Board in their meeting held on November 13, 2014. and Ms. Hemal Deasi, Non-Independent Director has been appointed as an Additional Director w.e.f. November 13, 2014.14 Nov · Results
Oct 2014
31 Oct · Board meeting
Amongst other things, to consider and take on record Unaudited Financial Results of the Company for the quarter ended September 30, 2014.
Sep 2014
29 Sep · Disclosure of Voting Pattern - Clause 35A
29 Sep · Meeting
At the Annual General Meeting held on September 26, 2014 the shareholders have approved following: Dividend of Rs. 0.05 per share of Re. 1 each 5% on the Equity Share Capital of the Company for the financial year ended 2013-14.29 Sep · Disclosure of Voting Pattern - Clause 35A
Aug 2014
28 Aug · Meeting
Company has fixed Book Closure from September 22, 2014 to September 26, 2014 (both days inclusive) for the purpose of Annual General Meeting of the Company to be held on September 26, 2014 and payment of dividend.28 Aug · Dividend
Board of Directors of the Company at its meeting held on August 27, 2014 has recommended a dividend of Re 0.05 per share on equity share of Rs.1/- each as a final dividend for the Financial Year 2013-14.28 Aug · Meeting
Board of Directors of the Company in their meeting held on August 27, 2014 has approved September 26, 2014 as date of Annual General Meeting of the members of the Company.19 Aug · Board meeting
Inter alia to consider :- (i) To consider and approve the draft notice convening the Annual General Meeting of the Company. (ii) To consider and approve the Auditors Report and the Directors Report including the annexures thereon on the Audited Financial Results of the Company for the Financial Year 2013-2014.19 Aug · Management
In the meeting of Board of Director held on August 14, 2014 Board has considered and approved the appointment of Mr. SantoshKumar Sharma as a Company Secretary of the company who would further act as a Compliance Officer w.e.f. June 17, 2014.14 Aug · Results
7 Aug · Board meeting
To consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2014.
Jul 2014
8 Jul · Legal
Price movement : Significant price movement has been observed in Gufic Biosciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Gufic Biosciences Limited has vide its letter inter-alia stated,"We would like to take your note that company has got recognition for In-House R&D unit(s) located at N.H. No. 8, Near Grid, Kablipore, Navsari, Gujarat from May 05th, 2014 to March 31st, 2017 from the Department of Scientific & Industrial Research (DSIR), Ministry of Science and Technology, Government of India".8 Jul · Management
W.e.f.June 17, 2014 Mr. Santoshkumar Sharma has been appointed as the Company Secretary of the Company in terms of Section 203 of the Companies Act, 2013. Further, Mr. Santoshkumar Sharma will also act as the Compliance Officer.
May 2014
31 May · Results
20 May · Management
Mr. Prakash Khulbe, Company Secretary and Compliance Officer of the Company has resigned from the Company with effect from the 20th April 2014.